Table 2 Audiometric and psychoacoustic characteristics of patients at screening (ITT population)
N | Mean ± SD | |
|---|---|---|
Puretone audiometry (worst ear) | ||
Hearing threshold [dB] | ||
Placebo | 111 | 19.9 ± 10.6 |
Neramexane 25 mg/d | 106 | 20.1 ± 12.6 |
Neramexane 50 mg/d | 106 | 19.4 ± 10.6 |
Neramexane 75 mg/d | 99 | 20.6 ± 14.7 |
High frequency hearing threshold [dB] | ||
Placebo | 111 | 36.9 ± 20.2 |
Neramexane 25 mg/d | 106 | 36.0 ± 21.4 |
Neramexane 50 mg/d | 106 | 36.6 ± 21.7 |
Neramexane 75 mg/d | 99 | 36.9 ± 19.9 |
Tinnitus matching (worst ear) | ||
Frequency (pitch) match [Hz] | ||
Placebo | 109 | 4577.5 ± 2601.9 |
Neramexane 25 mg/d | 105 | 4915.1 ± 2596.2 |
Neramexane 50 mg/d | 103 | 4958.7 ± 2683.1 |
Neramexane 75 mg/d | 97 | 4920.9 ± 2804.8 |
Loudness match [dB] | ||
Placebo | 105 | 38.6 ± 19.3 |
Neramexane 25 mg/d | 103 | 40.5 ± 20.5 |
Neramexane 50 mg/d | 99 | 39.3 ± 20.3 |
Neramexane 75 mg/d | 91 | 39.2 ± 18.5 |
Minimal masking level (worst ear) | ||
Masking level [dB] | ||
Placebo | 106 | 44.8 ± 21.0 |
Neramexane 25 mg/d | 100 | 46.8 ± 19.0 |
Neramexane 50 mg/d | 99 | 44.8 ± 21.1 |
Neramexane 75 mg/d | 92 | 44.2 ± 20.6 |